Navigation Links
Veracyte, Inc. Announces Third Quarter 2013 Financial Results
Date:11/25/2013

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2013 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2013, and provided an update on recent business progress. Revenue was $5.6 million for the third quarter of 2013, versus $3.2 million for the third quarter of 2012, an increase of 74%. Revenue for the first nine months of 2013 was $15.0 million, compared to $7.2 million for the first nine months of 2012, an increase of 110%.

"Our strong financial performance, including a 74% increase in year-over-year third quarter revenues, reflects both growing physician adoption and increased payer coverage and reimbursement for our Afirma solution. The results demonstrate increasing recognition of the value our product delivers in helping patients avoid unnecessary surgeries, while reducing healthcare costs," said Bonnie H. Anderson, Veracyte's president and chief executive officer. "Further, our recently completed initial public offering marks a significant milestone for the company, and we are encouraged by the interest of a high-caliber group of investors. These proceeds will enable us to accelerate our sales and marketing efforts in response to recent positive payer coverage decisions for our Afirma GEC. With our growth in adoption and reimbursement and the proceeds from our IPO, we believe we are well-positioned to advance the long-term growth of the company."

Recent Business Highlights

  • Obtained positive medical coverage policies for the Afirma GEC from Humana in July and SelectHealth, a part of Intermountain Healthcare, in August, following a positive coverage decision by Aetna in June.
  • Positive data from the first long-term, multicenter outcome study confirming the clinical validity and durable clinical utility of the Afirma GEC were published online in the Journal of Clinical Endocrinology &
    '/>"/>

  • SOURCE Veracyte
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
    2. Veracyte, Inc. Announces Pricing of Initial Public Offering
    3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
    4. Golden Meditech Announces 2013 / 2014 Interim Results
    5. iHealth Announces Results of AHA Walking Challenge
    6. Unilife Announces Results of 2013 Annual General Meeting
    7. Hanger Announces Appointment of Christopher B. Begley to Board of Directors
    8. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
    9. Array BioPharma Announces Management Team Change
    10. Hill-Rom Holdings, Inc. Announces First Quarter 2014 Dividend
    11. Argos Therapeutics Announces Additional $17.5 Million Of Series E Financing Bringing Total Commitment To $60 Million
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest Actos ... Las Vegas courtroom.  Attorneys representing two ... men suffered severe effects, including death, after using the diabetes ... what they as a company knew, that their drug Actos ... Robert Eglet .  "In order to hold Takeda responsible it ...
    (Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
    (Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
    Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
    (Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
    (Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
    (Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
    (Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and ... and pleads for swift actions to be taken in order to ease the ... , Yisrayl says scientists have yet to understand fully the real cause of global ...
    (Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
    Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
    ... may be beneficial in preventing severe long-term disability in multiple ... treatment for the chronic progressive phase of MS, when serious ... Children's Hospital Boston study appearing in the Journal of Neuroscience, ... type of vitamin B3 known as nicotinamide cut the risk ...
    ... help reduce Alzheimer's disease, says a study on mice, but ... findings apply to people.// ,Jun Wang and other researchers ... mice with genes that order the production of amyloid-beta protein, ... reported the online edition of science magazine WebMD. ...
    ... the basic purpose of a sunscreen lotion as well as ... well on the threshold of a discovery; Scientists have found ... the fair skin people from tanning as well as guard ... David E. Fisher, director of the Melanoma Program at the ...
    ... 80% of people suffering from severe chronic lung disease ... of it.// ,Chronic Bronchitis and Emphysema constitute the ... lung tissue by smoking can lead to the development ... ,Professor Robert West, director of tobacco studies at Cancer ...
    ... particularly those with high levels of low-density lipoprotein ... according to a study in the September 20 ... specific class of lipoprotein particles found in human ... according to background information in the article. Studies ...
    ... kidney cancer has been rising over the last two decades, ... Center shows// that this increase is driven largely by the ... the rising incidence has been paralleled by greater use of ... fewer people dying. ,“With increased early detection and treatment ...
    Cached Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
    The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
    Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
    ... The Invacare Digital Pulse ... and pulse strength. It is ... measurements on challenging patients. The ... other artifacts, informs the operator ...
    Rad-9™...
    Medicine Products: